Inspira Technologies (NASDAQ:IINN) has announced the approval of a second U.S. patent for VORTEX, its orbiting blood oxygenation delivery system designed to oxygenate blood without the use of fibre membranes, bringing the total number of patents for this technology to 32.
VORTEX, a key component of the company’s INSPIRA ART device, could revolutionize the medical field by reducing blood damage and costs associated with traditional fibre-based blood oxygenation technologies.
Each year, the majority of the 20 million intensive care patients suffering from respiratory failure depend on medical ventilators. The INSPIRA ART device helps maintain stable oxygen levels without requiring invasive ventilators that involve intubation and medically induced comas.
In a statement, Dagi Ben-Noon, CEO of Inspira, said, “We view this as another major leap forward in blood oxygenation technologies, representing another crucial milestone highlighting the core technological capabilities of the INSPIRA ART.”
